Clinical trial

Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children: a Multi-centre Placebo Controlled Randomised Trial in the United Kingdom

Name
17097AB-AS
Description
Short-sightedness, also called myopia, makes objects in the distance, such as the television, look blurred. This is caused by the eye growing too long, something that usually happens while children are also getting taller. People with myopia can see better with glasses or contact lenses, but this doesn't stop their eyes continuing to become more short-sighted. The CHAMP UK study is investigating a type of eye drop called atropine that might help to stop myopia getting worse as children get older.
Trial arms
Trial start
2019-04-03
Estimated PCD
2024-02-29
Trial end
2027-02-02
Status
Active (not recruiting)
Phase
Early phase I
Treatment
Atropine Sulfate
Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.
Arms:
Intervention Group (Atropine 0.01%)
Placebo
Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
Arms:
Placebo Group
Size
289
Primary endpoint
Spherical equivalent refractive error (i.e. myopia severity)
Baseline - 24-months
Eligibility criteria
Inclusion Criteria: 1. Age 6-12 years (at the time of consenting) 2. Myopia of -0.5D or greater (spherical equivalent refractive error) in both eyes 3. Best-corrected distance visual acuity (BCDVA) 0.20 logMAR or better in both eyes Exclusion Criteria: 1. Children with other ocular morbidities 2. Myopia of -10D or greater in either eye 3. Astigmatism of 2D or higher in either eye 4. Amblyopia 5. Significant health problems that can compromise the ability to attend research visits or complete the trial 6. Other factors that may compromise the ability to attend the research appointments 7. Parents or children with poor understanding of the English language 8. Children enrolled in other interventional trials 9. Allergy or hypersensitivity to atropine or excipients
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Multicentre, randomised, double-masked, placebo-controlled superiority trial', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'Double-masked', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 289, 'type': 'ESTIMATED'}}
Updated at
2023-09-07

1 organization

1 product

1 indication

Product
Atropine
Indication
Myopia